Tag: RRMS
NICE recommends Zinbryta (daclizumab) for relapsing-remitting multiple sclerosis
The National Institute for Health and Care Excellence (NICE) has recommended ZINBRYTA (daclizumab) from Biogen for the treatment of adult patients living with relapsing-remitting...
ECTRIMS and EAN join forces to formulate the first European MS...
A late-breaking session at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS; 14–17 September, London, UK) presented the Clinical Guideline on...
Tecfidera (dimethyl fumarate) real-world studies affirm sustained efficacy and demonstrate nine-year...
Biogen has announced new Tecfidera (dimethyl fumarate) data at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)...
Six year Lemtrada data presented at ECTRIMS
Sanofi Genzyme has announced the presentation six-year investigational data from the extension study of Lemtrada (alemtuzumab) in patients with relapsing remitting multiple sclerosis (RRMS)....